| 臺大學術典藏 |
2022-09-06T07:43:32Z |
Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: Correlates with operative procedures and duration after operation
|
Bair M.-J.; MING-SHIANG WU; Chang W.-H.; Shih S.-C.; Wang T.-E.; Chen C.-J.; Lin C.-C.; Liu C.-Y.; Chen M.-J. |
| 臺大學術典藏 |
2022-09-06T07:43:00Z |
Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance
|
Sheu B.-S.; Wu C.-Y.; MING-SHIANG WU; Chiu C.-T.; Lin C.-C.; Hsu P.-I.; Cheng H.-C.; Lee T.-Y.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2022-08-23T02:35:03Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-08-19T00:21:17Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Yeh K.-H.; Bu C.-F.; Lin C.-C.; Lu Y.-S.; Yang C.-H.; CHIUN HSU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; CHIUN HSU; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; CHIUN HSU; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; CHIUN HSU; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Ni Y.-H.; Lin C.-L.; Hsu Y.-C.; Hsu C.-W.; Wu C.-Y.; Wu J.-C.; Cheng J.C.-H.; Leung S.W.; Chen S.-W.; Hsu H.-C.; Hong J.-H.; Wang P.-M.; Wang P.-M.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; CHIUN HSU; Chao Y.; Chen L.-T.; Lee P.-H.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Hung C.-F.; Huang S.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-12T08:07:48Z |
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
|
Lee S.-H.; Lin C.-C.; Wei C.-H.; Chang K.-P.; CHANG-TSU YUAN; Tsai C.-H.; Liu J.-H.; Hou H.-A.; Tang J.-L.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-08-12T08:07:47Z |
Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair
|
Chen T.-C.; Yao C.-Y.; Chen Y.-R.; CHANG-TSU YUAN; Lin C.-C.; Hsu Y.-C.; Chuang P.-H.; Kao C.-J.; Li Y.-H.; Hou H.-A.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-08-12T06:27:47Z |
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker
|
Tseng C.-W.; Yang J.-C.; Chen C.-N.; Huang H.-C.; Chuang K.-N.; Lin C.-C.; Lai H.-S.; Lee P.-H.; KING-JEN CHANG; Juan H.-F. |
| 臺大學術典藏 |
2022-08-12T06:27:32Z |
Classification of benign and malignant breast tumors in ultrasound images with posterior acoustic shadowing using half-contour features
|
Zhou Z.; Wu S.; KING-JEN CHANG; Chen W.-R.; Chen Y.-S.; Kuo W.-H.; Lin C.-C.; Tsui P.-H. |
| 臺大學術典藏 |
2022-08-10T02:37:43Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; CHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-07-28T07:28:10Z |
Distinct Patterns of Amyloid Pathology in Autopsies of Transthyretin S77Y and A97S Amyloidosis: Significance of Symptomatology and Cell Biology
|
Chang K.; Yang W.-K.; Li W.-T.; Yeh T.-Y.; Jao C.-H.; Lin J.R.; Lin C.C.; Jeng Y.-M.; Chao C.-C.; SUNG-TSANG HSIEH |
| 臺大學術典藏 |
2022-07-26T08:09:28Z |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
Ma W.-L.; Lin C.-C.; Hsu F.-M.; Lee J.-M.; Chen J.-S.; Huang Y.-L.; YIH-LEONG CHANG; Chang C.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-06-30T02:06:27Z |
Developing A Rheological Relation for Transient Dense Granular Flows Via Discrete Element Simulation in A Rotating Drum
|
Lin C.-C.; Jiang M.-Z.; Yang F.-L.; MING-ZHE JIANG |
| 臺大學術典藏 |
2022-06-30T02:06:06Z |
Atomic-Layer Controlled Interfacial Band Engineering at Two-Dimensional Layered PtSe2/Si Heterojunctions for Efficient Photoelectrochemical Hydrogen Production
|
Chung C.-C.; Yeh H.; Wu P.-H.; Lin C.-C.; Li C.-S.; Yeh T.-T.; Chou Y.; Wei C.-Y.; Wen C.-Y.; Chou Y.-C.; Luo C.-W.; Wu C.-I.; Li M.-Y.; Li L.-J.; Chang W.-H.; Chen C.-W.; Chung C.-C.; Chou Y.-C.; YI-CHIA CHOU |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:44Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; Lin Z.-Z.; CHONG-JEN YU; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T. |
| 臺大學術典藏 |
2022-06-27T07:07:41Z |
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia
|
Hsiung C.A.; Lan Q.; Hong Y.C.; Chen C.-J.; Dean Hosgood H.; Chang I.-S.; Chatterjee N.; Brennan P.; Wu C.; Zheng W.; Chang G.-C.; Wu T.; Park J.Y.; Hsiao C.-F.; Kim Y.H.; Shen H.; Seow A.; Yeager M.; Tsai Y.-H.; Kim Y.T.; Chow W.-H.; Guo H.; Wang W.-C.; Sung S.W.; Hu Z.; Chen K.-Y.; Kim J.H.; Chen Y.; Huang L.; Lee K.-M.; Lo Y.-L.; Gao Y.-T.; Kim J.H.; Liu L.; Huang M.-S.; Jung T.H.; Jin G.; Caporaso N.; Yu D.; Kim C.H.; Su W.-C.; Shu X.-O.; Xu P.; Kim I.-S.; Chen Y.-M.; Ma H.; Shen M.; Cha S.I.; Tan W.; Chang C.-H.; Sung J.S.; Zhang M.; Yang T.-Y.; Park K.H.; Yuenger J.; Wang C.-L.; Ryu J.-S.; Xiang Y.; Deng Q.; Hutchinson A.; Kim J.S.; Cai Q.; Landi M.T.; CHONG-JEN YU; Park J.-Y.; Tucker M.; Hung J.-Y.; Lin C.-C.; Perng R.-P.; Boffetta P.; Chen C.-Y.; Chen K.-C.; Yang S.-Y.; Hu C.-Y.; Chang C.-K.; Fraumeni Jr. J.F.; Chanock S.; Yang P.-C.; Rothman N.; Lin D. |
| 臺大學術典藏 |
2022-06-27T07:06:22Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
